Is brown rice better than white rice? Intuitively, one would think that brown rice is much...
NASH Rapidly Overtaking Hepatitis C as a Cause of Liver Cancer
Tirzepatide vs. Semaglutide: Which Weight Loss Medication is Better?
Modern medical weight loss has been changed by the arrival of highly effective prescription...
The Wegovy Pill is Here: Is an Oral GLP-1 Right for You?
Recent clinical developments have introduced the Wegovy pill as a non-invasive option for those...
Menopause and Weight Gain: Why It Happens and What You Can Do About It
You’re Not Imagining It—Menopause Makes Weight Loss Harder Many women notice that once menopause...
Why does fat mass loss not always result in overall weight loss
Fat Mass Loss And Overall, Weight Loss It does—but not always immediately, and not always in a...
Lose the Weight or Lose the Leg
“Lose the weight or lose the leg.” It has been over 20 years since I heard these blunt words from...
Comments on article NASH rapidly overtaking hepatitis C as cause of liver cancer
BY BIANCA NOGRADY FROM THE JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY
I recently read this article and it struck me as something we should be paying more attention to.
Definitions
“NAFLD” describes hepatic steatosis with hepatocyte fat accumulation in a liver without inflammation.
“NASH” describes fat accumulation, hepatic inflammation and hepatocyte injury with or without fibrosis or cirrhosis.
Facts from the Article:
- NAFLD develops in the absence of significant alcohol abuse, hereditary disorders or causative medications and is often associated with obesity.
- The prevalence of NAFLD in the US is estimated to be 30-46% and is the most common form of liver disease in Western countries.
- The clinical predictors of advanced fibrosis in NAFLD include: hypertension, diabetes mellitus and visceral obesity.
- In 2015 NASH was the number one indication for liver transplantation in patients aged <50 years (surpassing HCV infection)!
- Weight loss of 3% can decrease hepatic steatosis (NAFLD), 5% can decrease inflammation (NASH), 7% can resolve NASH and 10% can regress fibrosis!
As Obesity Medicine physicians, we see patients with NAFLD/NASH every day. I have seen many patients with elevations in LFTs that normalize within several months of treatment. Not to mention the resolution of hypertension and DM2 as risk factors for NAFLD/NASH.










